レゴラフェニブ
レゴラフェニブ 物理性質
- 融点 :
- 206.0 to 210.0 °C
- 沸点 :
- 513.4±50.0 °C(Predicted)
- 比重(密度) :
- 1.491±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Refrigerator
- 溶解性:
- DMSO（微量）、メタノール（微量）
- 酸解離定数(Pka):
- 12.04±0.70(Predicted)
- 外見 :
- 白い粉。
- 色:
- 淡いピンク～淡いピンク
- CAS データベース:
- 755037-03-7
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露； 気道刺激性 |
3 |
警告 |
|
|
|
| 注意書き |
| P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
| P305+P351+P338 |
眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
東京化成工業
|
R0142 |
レゴラフェニブ >98.0%(HPLC)
Regorafenib
>98.0%(HPLC) |
755037-03-7 |
25mg |
￥13900 |
2024-03-01 |
購入 |
|
東京化成工業
|
R0142 |
レゴラフェニブ >98.0%(HPLC)
Regorafenib
>98.0%(HPLC) |
755037-03-7 |
100mg |
￥41200 |
2024-03-01 |
購入 |
レゴラフェニブ 化学特性,用途語,生産方法
外観
白色～うすい黄色～うすい黄赤色粉末～結晶
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
説明
In September 2012, theUSFDAapproved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC), especially those for whom standard therapies have failed, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, ananti-EGFRtherapy. Regorafenib is a multikinase inhibitor with potent inhibitory activity versus VEGFRs and PDFRs. Both of these classes of receptors are expressed on tumor cells and affect proliferation and angiogenesis. Regorafenib inhibited growth in murine xenograft models for colon, breast, renal, lung, melanoma, pancreatic, and ovarian tumors when dosed at 10–30 mg/kg. Regorafenib is a fluorinated analog of sorafenib, a multikinase inhibitor co-marketed by Bayer and Onyx for the treatment of kidney and liver cancer. The synthesis of regorafenib is accomplished in two steps from commercially available starting materials. 4-Aminophenol is coupled to 4-chloro-N-methyl- 2-pyridinecarboxamide to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. Subsequent treatment with 4-chloro-3-(trifluoromethyl)phenyl isocycanate affords the urea, regorafenib.
特性
Class: receptor tyrosine kinase
Treatment: colorectal cancer, GIST, HCC
Elimination half-life = 26-28 h
Protein binding = 99.5%
使用
BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.
定義
ChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ
usly received chemotherapy, anti-EGFR or anti-VEGF therapy.
レゴラフェニブ 上流と下流の製品情報
原材料
準備製品
レゴラフェニブ 生産企業
Global( 488)Suppliers
755037-03-7(レゴラフェニブ)キーワード:
- 755037-03-7
- 4-[4-({[4-chioro-3-(trifluoroMethyl)phenyl]carbaMoyl}aMino)-3-fluorophenoxy]-pyridine-2-carboxylic acid MethylaMide
- REGORAFENIB BAY 73-4506 BAYER HEALTHCARE (SEE ALSO COLORECTAL, LUNG, STOMACH) PHASE II(REGORAFENIB) PHARMACEUTICALS (888) 842-2937WAYNE, NJ
- 4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]-3-fluorophenoxy]-N-Methyl-2-pyridinecarboxaMide
- 4-[4-[N'-(4-Chloro-3-trifluoroMethylphenyl)ureido]-3-
fluorophenoxy]pyridine-2-carboxylic Acid MethylaMide
- regorafinib
- Regafenib
- Reggae sorafenib
- Regorafenib C3X-1410
- Regorafenib, >=98%
- 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea
- Fluoro-Sorafenib
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide Regorafenib BAY 73-4506
- Stivarga(regorafenib)
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide
- Regorafenib
- BAY 73-4506
- BAY 73-4506(Regorafenib)
- 4-(4-(3-(4-chloro-3-(trifluoroMethyl)phenyl)ureido)-3-fluorophenoxy)-N-MethylpicolinaMide
- 842-2937WAYNE
- China Hot sale Regorafenib with best price and high quality CAS NO.755037-03-7
- CS-1930
- Regorafenib - BAY 73-4506 | Stivarga
- CS-169
- Regorafenib (BAY73-4506,Fluoro-Sorafenib)
- REGORAFENIB; BAY 73-4506; SORAFENIB; BAY-73-4506; BAY 73 4506
- Regorafenib(W.S)
- Re orafenib
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-3-carboxamide
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-...
- レゴラフェニブ
- 4-[4-({[4-クロロ-3-(トリフルオロメチル)フェニル]カルバモイル}アミノ)-3-フルオロフェノキシ]-N-メチルピリジン-2-カルボキサミド
- スチバーガ
- 4-[4-[3-[4-クロロ-3-(トリフルオロメチル)フェニル]ウレイド]-3-フルオロフェノキシ]-N-メチル-2-ピリジンカルボアミド